The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

XII. Cardiovascular involvement / toxicity

XII.p QTc prolongation

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.p Fatal pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.w Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

V. Pleural and/or pericardial involvement

V.f Pneumothorax

V. Pleural and/or pericardial involvement

V.p Pleuroparenchymal fibroelastosis (PPFE)

V. Pleural and/or pericardial involvement

V.z Pneumothorax (associated or secondary to drug-induced ILD)

VI. Pulmonary vasculopathy

VI.c Pulmonary veno-occlusive disease

VI. Pulmonary vasculopathy

VI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

VII. Mediastinal involvement

VII.e Granulomatous mediastinal lymphadenopathy

VII. Mediastinal involvement

VII.h Pneumomediastinum

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.c Pleuritic chest pain

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.j Path: Pulmonary fibrosis (UIP-pattern)

XV. Pathology

XV.l Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XV. Pathology

XV.ax Path: Focal organizing pneumonia

XV. Pathology

XV.be Path: Interstitial pulmonary edema

XV. Pathology

XV.bf Path: Pulmonary necrotizing granuloma or granulomas

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.af Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.j Eye-catcher: Avid lung uptake on 18F-PET-CT

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XXIV. Veterinary medicine

XXIV.a Veterinary: Pneumonitis - Interstitial lung disease

XXIV. Veterinary medicine

XXIV.b Veterinary: Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.x Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.ad Radiation recall pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.f Pneumothorax

V. Pleural and/or pericardial involvement

V.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

V. Pleural and/or pericardial involvement

V.ab Pneumothorax, bilateral

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XV. Pathology

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.i Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XV. Pathology

XV.ap Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.m Imaging: Interlobular septal thickening

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.e Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.m ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.n Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.u Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.v Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.aw Persistent reduction in diffusing capacity for CO upon resolution of the adverse effect

I. Interstitial/parenchymal lung disease

I.ax Chronic pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Cough (lone)

IV. Airway involvement

IV.f Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.k Bronchiectasis

IV. Airway involvement

IV.n Obstructive airway dysfunction (see also IVc, XVx)

IV. Airway involvement

IV.p Thermal, chemical or caustic airway injury

IV. Airway involvement

IV.q Reactive airway dysfunction syndrome (RADS)

IV. Airway involvement

IV.t Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.v Deterioration/exacerbation of preexisting asthma or COPD

IV. Airway involvement

IV.ad Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.al Sputum production - Bonchorrhea - ‘Bronchitis’

V. Pleural and/or pericardial involvement

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

V. Pleural and/or pericardial involvement

V.f Pneumothorax

VII. Mediastinal involvement

VII.a Lymphadenopathy (intrathoracic)

VII. Mediastinal involvement

VII.e Granulomatous mediastinal lymphadenopathy

VII. Mediastinal involvement

VII.h Pneumomediastinum

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.d Thermal (burns, frostbite), chemical or caustic injury on the face, mouth, tongue, pharynx or upper airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.al Epiglottitis

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.an Facial/labial/buccal/oral/dental trauma

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.ap Airway foreign body

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.at Gross tracheal inflammation on endoscopy

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.aw Foreign body in the airway

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.bb Tracheitis including eosinophilic tracheal inflammation

VIII. Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.bc Tracheal redness/inflammation on gross endoscopic examination

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.h Dyspnea, unexplained otherwise

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.af Seizures

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.k Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.q Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.aq Relapse or flare of preexisting ulcerative colitis

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.r Death following exposure or poisoning

XI. Miscellaneous

XI.ac Thermal skin/dermal injury

XI. Miscellaneous

XI.ay Chest tightness

XI. Miscellaneous

XI.bc Polycythemia

XI. Miscellaneous

XI.bd Nicotine poisoning

XI. Miscellaneous

XI.be Burns

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.l Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.ag Bradycardia

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.a Methemoglobinemia

XV. Pathology

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XV. Pathology

XV.d Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV. Pathology

XV.g Path: Alveolar hemorrhage (see also IIIa)

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XV. Pathology

XV.x Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XV. Pathology

XV.y Path: Respiratory bronchiolitis (w/wo the RB-ILD-pattern)

XV. Pathology

XV.ab Path: Pulmonary capillaritis

XV. Pathology

XV.ba Path: Granulomatous lymphadenopathy

XV. Pathology

XV.bi Path: Giant-cell interstitial pneumonia (GIP)-pattern

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.d Imaging: Alveolar opacities or haze with a batwing or butterfly distribution

XVI. Imaging

XVI.g Imaging: Diffuse whiteout/alveolar shadowing (see also under IIb-ARDS)

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.af Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.ai Imaging: A 'tree-in-bud' pattern

XVI. Imaging

XVI.bl Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVII. Infections & related conditions

XVII.a Respiratory tract infection incl. pneumonia

XVII. Infections & related conditions

XVII.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVII. Infections & related conditions

XVII.ac Actinomycosis

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.x Eye catcher: A batwing pattern on imaging

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.b BAL: An excess proportion of neutrophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.c BAL: An excess proportion of eosinophils

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.d BAL: Gross or microscopic bleeding/hemorrhage

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.f BAL: Foamy macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.i BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.n BAL: Brown-pigmented macrophages

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.j Exogenous lipoid pneumonia (subacute, acute)

I. Interstitial/parenchymal lung disease

I.k Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.s A mass or masses

I. Interstitial/parenchymal lung disease

I.z An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ap Paraffinoma - Lipidoma (ELP in the form of a nodule or mass)

II. Pulmonary edema - Acute lung injury - ARDS

II.b ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

IV. Airway involvement

IV.w Plugs/casts in the airways

VII. Mediastinal involvement

VII.o Lipid-laden mediastinal lymphadenopathy

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

XIII. Neoplastic conditions

XIII.a Lung cancer

XV. Pathology

XV.e Path: ILD with a granulomatous component (see also Im)

XV. Pathology

XV.h Path: NSIP-fibrotic pattern

XV. Pathology

XV.p Path: Exogenous lipoid pneumonia

XV. Pathology

XV.q Path: Foreign body deposits/granulomatous reaction

XV. Pathology

XV.dd Path: Exogenous lipid-laden lymphadenopathy

XVI. Imaging

XVI.a Imaging: Diffuse haze

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.f Imaging: Bibasilar opacities/shadowing

XVI. Imaging

XVI.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.n Imaging: Intralobular septal thickening - Crazy paving

XVI. Imaging

XVI.r Imaging: An area or areas of involvement with low attenuation numbers

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.z Imaging: A large nodule or a mass

XVI. Imaging

XVI.ab Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.az Imaging: Solitary pulmonary nodule

XVI. Imaging

XVI.bc Imaging: Intrathoracic lymph node enlargement

XVII. Infections & related conditions

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

XVIII. Distinctive patterns - 'Eye-catchers'

XVIII.r Eye catcher: A milky, cloudy or lumpy BAL fluid

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.a BAL: An excess proportion of lymphocytes

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.h BAL: Exogenous (oil red O-stainable) lipids in BAL macrophages

XIX. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XIX.j BAL: Free exogenous lipids in supernatant

XXIV. Veterinary medicine

XXIV.f Veterinary: Exogenous lipoid pneumonia